Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.00

Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio is 0.00 for the year ending December 31, 2023, a -25.39% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.00, a -66.18% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.00, a -57.28% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.00, a -95.43% change year over year.
  • Shanghai Allist Pharmaceuticals Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.09, a -94.72% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
Shanghai Stock Exchange: 688578.SS

Shanghai Allist Pharmaceuticals Co., Ltd.

CEO Mr. Jinhao Du
IPO Date Dec. 2, 2020
Location China
Headquarters No. 268 Lingxiaohua Road
Employees 1,044
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Shanghai Allist Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in China. It offers pharmaceuticals for the treatment of tumor and cancer diseases. The company was founded in 2004 and is based in Shanghai, China.

StockViz Staff

February 2, 2025

Any question? Send us an email